Janjigian YY - Search Results

1

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. Janjigian YY, et al. Nature. 2021 Dec;600(7890):727-730. doi: 10.1038/s41586-021-04161-3. Epub 2021 Dec 15. Nature. 2021. PMID: 34912120 Free PMC article. Clinical Trial.

2

Molecularly targeted therapies in advanced gastric cancer.

Janjigian YY, Shah MA. Janjigian YY, et al. Minerva Gastroenterol Dietol. 2011 Mar;57(1):75-88. Minerva Gastroenterol Dietol. 2011. PMID: 21372772 Review.

3

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Janjigian YY, et al. Ann Oncol. 2012 Oct;23(10):2656-2662. doi: 10.1093/annonc/mds104. Epub 2012 Jun 11. Ann Oncol. 2012. PMID: 22689179 Free article.

4

Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.

Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS. Janjigian YY, et al. J Nucl Med. 2013 Jun;54(6):936-43. doi: 10.2967/jnumed.112.110239. Epub 2013 Apr 11. J Nucl Med. 2013. PMID: 23578997 Free PMC article.

5

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.

Janjigian YY, Vakiani E, Ku GY, Herrera JM, Tang LH, Bouvier N, Viale A, Socci ND, Capanu M, Berger M, Ilson DH. Janjigian YY, et al. PLoS One. 2015 Aug 14;10(8):e0134731. doi: 10.1371/journal.pone.0134731. eCollection 2015. PLoS One. 2015. PMID: 26275293 Free PMC article. Clinical Trial.

6

Lapatinib in Gastric Cancer: What Is the LOGiCal Next Step?

Janjigian YY. Janjigian YY. J Clin Oncol. 2016 Feb 10;34(5):401-3. doi: 10.1200/JCO.2015.64.2892. Epub 2015 Dec 23. J Clin Oncol. 2016. PMID: 26700116 No abstract available.

7

Clinical impact of tumour biology in the management of gastroesophageal cancer.

Lordick F, Janjigian YY. Lordick F, et al. Among authors: janjigian yy. Nat Rev Clin Oncol. 2016 Jun;13(6):348-60. doi: 10.1038/nrclinonc.2016.15. Epub 2016 Mar 1. Nat Rev Clin Oncol. 2016. PMID: 26925958 Free PMC article. Review.

8

The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond.

Kelly CM, Janjigian YY. Kelly CM, et al. Among authors: janjigian yy. J Gastrointest Oncol. 2016 Oct;7(5):750-762. doi: 10.21037/jgo.2016.06.10. J Gastrointest Oncol. 2016. PMID: 27747089 Free PMC article. Review.

9

New agents on the horizon in gastric cancer.

Lordick F, Shitara K, Janjigian YY. Lordick F, et al. Among authors: janjigian yy. Ann Oncol. 2017 Aug 1;28(8):1767-1775. doi: 10.1093/annonc/mdx051. Ann Oncol. 2017. PMID: 28184417 Free article. Review.

10

Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer.

Janjigian YY, Braghiroli MI. Janjigian YY, et al. Surg Oncol Clin N Am. 2017 Apr;26(2):313-324. doi: 10.1016/j.soc.2016.10.005. Epub 2017 Feb 10. Surg Oncol Clin N Am. 2017. PMID: 28279471 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

166 results

Search Page